(Q53557378)

15 May 2018

title

Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. (English)

1 reference

15 May 2018

1 reference

5

Brad H Rovin

1 reference

15 May 2018

author name string

Daniel Roncone

1

1 reference

15 May 2018

Anjali Satoskar

2

1 reference

15 May 2018

Tibor Nadasdy

3

1 reference

15 May 2018

J Paul Monk

4

1 reference

15 May 2018

publication date

1 May 2007

1 reference

15 May 2018

Nature Clinical Practice Nephrology

published in

1 reference

15 May 2018

volume

3

1 reference

15 May 2018

issue

5

1 reference

15 May 2018

page(s)

287-293

1 reference

15 May 2018

Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Managing patients treated with bevacizumab combination therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Renal thrombotic microangiopathy induced by interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Preeclampsia: a renal perspective

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0476

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0476

1 reference

15 May 2018

1 reference

15 May 2018